4. Hypertension: Leading cause of death Ezzati et al. WHO 2000 Report. Lancet. 2002;360:1347-1360. Attributable Mortality (In millions) High mortality, developing region Lower mortality, developing region Developed region 0 8 7 6 5 4 3 2 1 High blood pressure Tobacco High cholesterol Unsafe sex High BMI Physical inactivity Alcohol Indoor smoke from solid fuels Iron deficiency Underweight
7. Hypertension prevalence world-wide WHO Report 2004; 2. Wolf-Maier K et al. Hypertension 2004. Italy 38% Spain 47% England 42% Germany 55% Canada 27% U.S.A. 28% Sweden 38%
8. Hypertension control world-wide Finland 21% Italy 9-23% Spain 5-16% France 27% England 6-10% Scotland 18% Germany 8-23% Canada 16-17% U.S.A. 29-31% Sweden 6% BP<140/90 35-64 years WHO Report 2004; 2. Wolf-Maier K et al. Hypertension 2004.
12. Blood Pressure and risk of Stroke Mortality MRFIT trial. Arch Intern Med 1992; 152:56-64
13. Blood Pressure and risk of CAD Mortality MRFIT trial . Arch Intern Med 1992; 152:56-64
14. Estimated Cumulative Incidence of Morbid Events in Untreated and Treated Hypertensive Patients *Including events such as hemorrhages, uncontrolled heart failure, diastolic blood pressure above specified limits, and cardiac, central nervous system, and renal events Veterans Administration Cooperative Study Group JAMA 1970;213(7):1143-1152
17. BP Classification 2007 ESC/ESH Guidelines for the management of Arterial Hypertension. J Hypertens. 2007;25:1105-1187.
18. BP threshold with different types of measurement 2007 ESC/ESH Guidelines for the management of Arterial Hypertension. J Hypertens. 2007;25:1105-1187.
19. Risk Stratification 2007 ESC/ESH Guidelines for the management of Arterial Hypertension. J Hypertens. 2007;25:1105-1187.
20. When to initiate antihypertensive treatment? 2007 ESC/ESH Guidelines for the management of Arterial Hypertension. J Hypertens. 2007;25:1105-1187.
57. Diuretics: The cornerstone of hypertension treatment 1. Chobanian AV, Bakris GL, Black HR, et al. (JNC-7). Hypertension. 2003;42:1206-1252. 2. WHO, ISH writing group statement on management of hypertension. J Hypertens. 2003;21:1983-1992 They enhance the antihypertensive efficacy of all other antihypertensive drugs
58. Conclusion 1. The ALLHAT study JAMA. 2002; 288: 2981-2997 2. JNC - VII Report, JAMA , 2003;289:2560-2572